SEATTLE, Feb. 05, 2018 (GLOBE NEWSWIRE)-- NanoString Technologies, Inc. (NASDAQ: NSTG), a provider of life science tools for translational research and molecular
diagnostic products, today announced the publication of a landmark study in which Danish researchers used the Prosigna ® Breast Cancer
Assay risk of recurrence (ROR) score to accurately predict rates of 10 - year distant recurrence (DR) of cancer in a comprehensive and population - based cohort including all postmenopausal women in Denmark with early - stage hormone receptor (HR)-
positive, Her - 2 negative breast cancer who received 5 years of adjuvant endocrine therapy according to nationwide guidelines between 2000 and 2003.
A potential problem is that vaccinated cats will also test
positive on the routine tests used to detect FIV - infected cats, but newer
diagnostic assays are becoming available that may overcome this problem.